Imatinib resistance in chronic myelogenous leukemia is frequently associated with either ABL kinase mutations or with secondary rearrangements of the BCR-ABL

被引：0
|
作者：
Yin, C [1 ]
Luthra, R [1 ]
Cortes, J [1 ]
Reeves, N [1 ]
Hayes, K [1 ]
Glassman, A [1 ]
Kantarjian, H [1 ]
Jones, D [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2004年 / 6卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
H8
引用
收藏
页码：416 / 416
页数：1
相关论文
共 50 条
  • [31] Decreasing BCR-ABL level in contrast to the BCR-ABL load at the start of treatment, is significantly associated with the cytogenetic response to imatinib in chronic myelogenous leukemia patients.
    Colombat, M
    Chollet, C
    Fort, MP
    Barthe, C
    Leguay, T
    Bilhou-Nabera, C
    Reiffers, J
    Marit, G
    Mahon, FX
    BLOOD, 2002, 100 (11) : 319B - 319B
  • [32] BCR-ABL kinase domain mutations and clonal evolution as major causes of resistance to targeted therapy in chronic myelogenous leukemia
    Andrikovics, H.
    Meggyesi, N.
    Lueff, S.
    Batai, A.
    Adam, E.
    Kozma, A.
    Halm, G.
    Nahajevszky, S.
    Kapas, B.
    Csukly, Z.
    Lovas, N.
    Remenyi, P.
    Tordai, A.
    Masszi, T.
    BLOOD REVIEWS, 2007, 21 : S78 - S79
  • [33] BCR-ABL REARRANGEMENTS IN CHILDREN WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA
    AURER, I
    BUTTURINI, A
    GALE, RP
    BLOOD, 1991, 78 (09) : 2407 - 2410
  • [34] Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels -: Response
    Corbin, A
    La Rosée, P
    Stoffregen, E
    Druker, B
    Deininger, M
    BLOOD, 2003, 102 (05) : 1934 - 1935
  • [35] Evaluation of BCR-ABL/ABL Ratio Increase That Corresponds to BCR-ABL Mutation In Chronic Myeloid Leukemia Patients Treated by Imatinib
    Tsaur, Grigory
    Ivanova, Anna
    Popov, Alexander
    Yakovleva, Yulia
    Riger, Tatyana
    Plekhanova, Olga
    Ivanets, Yulia
    Misyurin, Andrey
    Suchkova, Marina
    Shorikov, Egor
    Saveliev, Leonid
    Fechina, Larisa
    BLOOD, 2010, 116 (21) : 1402 - 1402
  • [36] INCREASING BCR-ABL EXPRESSION LEVELS AND/OR OCCURRENCE OF ABL POINT MUTATIONS NOT ALWAYS PREDICT RESISTANCE TO IMATINIB MESYLATE IN BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
    Grammatico, S.
    Elia, L.
    Vitale, A.
    Matarazzo, M.
    Falciani, V
    Rago, A.
    Cenfra, N.
    Peluso, A. L.
    Pedace, L.
    Grammatico, P.
    Pane, F.
    Meloni, G.
    Foa, R.
    Cimino, G.
    HAEMATOLOGICA, 2008, 93 : S88 - S89
  • [37] Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia
    Sun, Xiaoyan
    Cai, Xueting
    Yang, Jie
    Chen, Jiao
    Guo, Caixia
    Cao, Peng
    MOLECULES AND CELLS, 2016, 39 (12) : 869 - 876
  • [38] BCR-ABL in chronic myelogenous leukemia - How does it work?
    Goldman, John M.
    Melo, Junia V.
    ACTA HAEMATOLOGICA, 2008, 119 (04) : 212 - 217
  • [39] Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells
    J. L. Fernandez-Luna
    Apoptosis, 2000, 5 : 315 - 318
  • [40] Is another Bcr-Abl inhibitor needed for chronic myelogenous leukemia?
    Sausville, EA
    CLINICAL CANCER RESEARCH, 2003, 9 (04) : 1233 - 1234
12345